✦ LIBER ✦

Oral pentasa in the treatment of active Crohn?s disease: A meta-analysis of double-blind, placebo-controlled trials

✍ Scribed by HANAUER, S

Book ID: 123096981
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 132 KB
Volume: 2
Category: Article
ISSN: 1542-3565
DOI: 10.1016/S1542-3565(04)00122-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of oral pentasa® 4g/day in trea

Efficacy of oral pentasa® 4g/day in treatment of active Crohn's disease: a meta-analysis double-blind, placebo-controlled trials

✍ Hanauer, Stephen B.; Stromberg, Ulf 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Prevention of relapse by mesalazine (Pen

Prevention of relapse by mesalazine (Pentasa®) in pediatric Crohn's disease: A multicenter, double-blind, randomized, placebo-controlled trial

✍ J.-P. Cezard; A. Munck; O. Mouterde; A. Morali; C. Lenaerts; A. Lachaux; D. Turc 📂 Article 📅 2009 🏛 Masson Editeur 🌐 French ⚖ 961 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease

✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

✍ J. C. MANSFIELD; M. PARKES; A. B. HAWTHORNE; A. FORBES; C. S. J. PROBERT; R.C. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients

Treatment of chronic venous diseases wit

Treatment of chronic venous diseases with oral glycosaminoglycans: A meta-analysis of double-blind, placebo-controlled studies

✍ Pierantonio Ferrari; Marco Follet; Giuseppina Clerici 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 498 KB